ValuEngine upgraded shares of Merus (NASDAQ:MRUS) from a hold rating to a buy rating in a report released on Monday morning.
MRUS has been the subject of a number of other research reports. BidaskClub upgraded shares of Merus from a buy rating to a strong-buy rating in a report on Saturday. Zacks Investment Research upgraded shares of Merus from a hold rating to a buy rating and set a $20.00 price objective for the company in a report on Friday, May 4th. Finally, Wedbush restated an outperform rating and set a $32.00 price objective (up previously from $26.00) on shares of Merus in a report on Monday, April 30th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $28.50.
Shares of NASDAQ MRUS opened at $23.55 on Monday. Merus has a 52-week low of $13.30 and a 52-week high of $24.05.
Merus (NASDAQ:MRUS) last issued its quarterly earnings data on Thursday, April 26th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter. The firm had revenue of $4.49 million for the quarter. Merus had a negative net margin of 530.70% and a negative return on equity of 91.14%. analysts forecast that Merus will post -3.67 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Deutsche Bank AG lifted its stake in Merus by 146.6% in the fourth quarter. Deutsche Bank AG now owns 9,400 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 5,588 shares in the last quarter. Millennium Management LLC bought a new position in Merus in the first quarter valued at approximately $267,000. Stanley Laman Group Ltd. bought a new position in Merus in the first quarter valued at approximately $860,000. Bain Capital Public Equity Management LLC bought a new position in Merus in the fourth quarter valued at approximately $8,297,000. Finally, Sofinnova Ventures Inc bought a new position in Merus in the first quarter valued at approximately $36,338,000. 43.31% of the stock is currently owned by hedge funds and other institutional investors.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.